BIO-TECHNE Corp Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent
BIO-TECHNE Corp (TECH) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent of $154.00 thousand for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-06.
Discontinued › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent · last filed 2019-11-06
- BIO-TECHNE Corp other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax, parent for the quarter ending 2019-09-30 was $154.00K.
- BIO-TECHNE Corp other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax, parent for fiscal 2019 was $2.92M.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent 12 month |
|---|---|---|
| 2019-09-30 | $154.00K 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $2.92M 10-K/A · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |